Amarin Corporation will present new EPA data at the ACC Annual Scientific Session, exploring cardiovascular risk reduction mechanisms.
Quiver AI Summary
Amarin Corporation announced the presentation of new in vitro data on eicosapentaenoic acid (EPA) at the American College of Cardiology's Annual Scientific Session & Expo from March 29-31, 2025. The data will focus on EPA's potential to reduce cardiovascular events in at-risk patients, especially when combined with emerging treatments like GLP-1 receptor agonists. Steve Ketchum, Amarin's EVP and Chief Scientific Officer, emphasized the importance of understanding EPA's antioxidative effects and its role alongside other therapies in managing cardiovascular risk. Additionally, the company looks to address the significant cardiovascular risk that remains even in patients treated with statins, especially those with elevated triglyceride levels.
Potential Positives
- Amarin Corporation is presenting additional in vitro mechanistic data on eicosapentaenoic acid (EPA) at a major scientific conference, which can enhance its credibility and visibility in the cardiovascular health space.
- The data to be presented suggests potential synergistic effects of EPA in combination with emerging GLP-1 receptor agonist therapies, indicating innovative applications that can diversify treatment options for cardiovascular risk management.
- The positive scientific dialogue surrounding VASCEPA/VAZKEPA reaffirms Amarin's commitment to advancing cardiovascular disease treatment and increasing understanding of residual CV risk.
Potential Negatives
- The press release emphasizes ongoing research and the need for further mechanistic understanding of EPA, suggesting uncertainty about the current effectiveness of existing treatments.
- There is mention of additional risks associated with VASCEPA, including increased rates of atrial fibrillation and bleeding, which may raise concerns among healthcare providers and patients regarding its safety profile.
- The continued emphasis on the "unmet need" for treatment beyond traditional therapies implies that current offerings, including VASCEPA, may not sufficiently address cardiovascular risk, potentially impacting market confidence.
FAQ
What new data will Amarin present at ACC.25?
Amarin will present additional in vitro mechanistic data on eicosapentaenoic acid (EPA) and its effects on cardiovascular risk.
When is the American College of Cardiology's Annual Session?
The American College of Cardiology’s Annual Scientific Session & Expo will take place from March 29-31, 2025, in Chicago, IL.
What is the role of EPA in cardiovascular treatment?
EPA is explored for its potential to reduce cardiovascular events, especially in high-risk patients on statin therapy.
What are the implications of combining EPA with GLP-1 receptor agonists?
Combining EPA with GLP-1 receptor agonists may enhance the expression of protective proteins during inflammation in endothelial cells.
What is VASCEPA and its indications?
VASCEPA (icosapent ethyl) is indicated to reduce cardiovascular risk in patients with elevated triglyceride levels and established cardiovascular disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AMRN Hedge Fund Activity
We have seen 46 institutional investors add shares of $AMRN stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DG CAPITAL MANAGEMENT, LLC removed 5,115,747 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $3,207,061
- PRICE JENNIFER C. removed 2,380,000 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $1,492,022
- MORGAN STANLEY added 1,860,670 shares (+73.1%) to their portfolio in Q4 2024, for an estimated $902,424
- EVERSEPT PARTNERS, LP removed 1,792,717 shares (-54.2%) from their portfolio in Q4 2024, for an estimated $869,467
- WATERFRONT WEALTH INC. added 1,599,956 shares (+181.4%) to their portfolio in Q4 2024, for an estimated $775,978
- ACADIAN ASSET MANAGEMENT LLC added 1,522,786 shares (+579.0%) to their portfolio in Q4 2024, for an estimated $738,551
- GSA CAPITAL PARTNERS LLP added 1,097,040 shares (+inf%) to their portfolio in Q4 2024, for an estimated $532,064
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DUBLIN and BRIDGEWATER, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional
in vitro
mechanistic data with eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology’s Annual Scientific Session & Expo, March 29-31, 2025, in Chicago, IL.
“At Amarin, we continue to invest in the science behind VASCEPA/VAZKEPA to further explore the potential mechanistic activities of EPA, administered clinically in the form of our icosapent ethyl product, to reduce cardiovascular (CV) events in at-risk patients,” said Steve Ketchum, EVP, President of R&D and Chief Scientific Officer at Amarin. ”With the advancement of additional therapeutic agents targeting other biological pathways and other domains of residual CV risk, Amarin’s research funding and scientific efforts become even more important. There may be additional biological benefits - via overlapping or distinct protective mechanisms - when combining EPA with emerging therapies like GLP-1 receptor agonists, which have been clearly shown to reduce CV risk on top of LDL-C lowering statin therapy,” added Ketchum.
“The data being presented at ACC.25 will provide further
in vitro
mechanistic evidence on the biological activities of EPA, specifically on the antioxidant effects of EPA on lipoprotein(a) [Lp(a)]-enriched plasma and on the effects of a GLP-1 receptor agonist in combination with EPA on the expression of antioxidant proteins in endothelial cells during inflammation,” concluded Ketchum.
Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2025 include:
Moderated Poster Presentations
More Rapid Oxidation of Lipoprotein(a) [Lp(a)]-enriched Plasma Compared to Small Dense- and Triglyceride-rich Lipoproteins is Limited by Eicosapentaenoic Acid (EPA)
Samuel C.R. Sherratt, PhD, Peter Libby, MD, Richard L. Dunbar, MD, Deepak L Bhatt, MD, MPH, MBA, R. Preston Mason, PhD, MBA
- Available March 29
th
, 11:30am ET
- Moderated Poster Theater 2
Addition of Eicosapentaenoic Acid (EPA) to a GLP-1 Agonist Enhanced Expression of Detoxification Proteins in Endothelial Cells During Inflammation in Vitro
Samuel C.R. Sherratt, PhD, Peter Libby, MD, Richard L. Dunbar, MD, Deepak L Bhatt, MD, MPH, MBA, R. Preston Mason, PhD, MBA
- Available March 29
th
, 11:42am ET
- Moderated Poster Theater 2
About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, Zug in Switzerland, and other countries in Europe as well as commercial partners and suppliers around the world.
About Cardiovascular Risk
Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year.
1
And the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds.
Controlling bad cholesterol, also known as LDL-C, is one way to reduce a patient’s risk for cardiovascular events, such as heart attack, stroke or death. However, even with the achievement of target LDL-C levels, millions of patients still have significant and persistent risk of cardiovascular events, especially those patients with elevated triglycerides. Statin therapy has been shown to control LDL-C, thereby reducing the risk of cardiovascular events by 25-35%.
2
Significant cardiovascular risk remains after statin therapy. People with elevated triglycerides have 35% more cardiovascular events compared to people with normal (in range) triglycerides taking statins.
3
,
4
About VASCEPA
®
/VAZKEPA
®
(icosapent ethyl) Capsules
VASCEPA (icosapent ethyl) capsules are the first prescription treatment approved by the U.S. Food and Drug Administration (FDA) comprised solely of the active ingredient, icosapent ethyl (IPE), a unique form of eicosapentaenoic acid. VASCEPA was launched in the United States in January 2020 as the first drug approved by the U.S. FDA for treatment of the studied high-risk patients with persistent cardiovascular risk despite being on statin therapy. VASCEPA was initially launched in the United States in 2013 based on the drug’s initial FDA approved indication for use as an adjunct therapy to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Since launch, VASCEPA has been prescribed more than twenty million times. VASCEPA is covered by most major medical insurance plans. In addition to the United States, VASCEPA is approved and sold in Canada, China, Lebanon and the United Arab Emirates. In Europe, in March 2021 marketing authorization was granted to icosapent ethyl in the European Union for the reduction of risk of cardiovascular events in patients at high cardiovascular risk, under the brand name VAZKEPA. In April 2021 marketing authorization for VAZKEPA (icosapent ethyl) was granted in Great Britain (applying to England, Scotland and Wales). VAZKEPA (icosapent ethyl) is currently approved and sold in Europe in Sweden, Denmark, Finland, Austria, the UK, Spain and the Netherlands.
United States
Indications and Limitation of Use
VASCEPA is indicated:
As an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and
established cardiovascular disease or
diabetes mellitus and two or more additional risk factors for cardiovascular disease.
As an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia.
The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.
Important Safety Information
VASCEPA is contraindicated in patients with known hypersensitivity (e.g., anaphylactic reaction) to VASCEPA or any of its components.
VASCEPA was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization in a double-blind, placebo-controlled trial. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.
It is not known whether patients with allergies to fish and/or shellfish are at an increased risk of an allergic reaction to VASCEPA. Patients with such allergies should discontinue VASCEPA if any reactions occur.
VASCEPA was associated with an increased risk (12% vs 10%) of bleeding in a double-blind, placebo-controlled trial. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.
Common adverse reactions in the cardiovascular outcomes trial (incidence ≥3% and ≥1% more frequent than placebo): musculoskeletal pain (4% vs 3%), peripheral edema (7% vs 5%), constipation (5% vs 4%), gout (4% vs 3%), and atrial fibrillation (5% vs 4%).
Common adverse reactions in the hypertriglyceridemia trials (incidence >1% more frequent than placebo): arthralgia (2% vs 1%) and oropharyngeal pain (1% vs 0.3%).
Adverse events may be reported by calling 1-855-VASCEPA or the FDA at 1-800-FDA-1088.
Patients receiving VASCEPA and concomitant anticoagulants and/or anti-platelet agents should be monitored for bleeding.
FULL U.S. FDA-APPROVED VASCEPA
PRESCRIBING INFORMATION
CAN
BE FOUND AT
WWW.VASCEPA.COM
.
Europe
For further information about the Summary of Product Characteristics (SmPC) for VAZKEPA
®
in Europe, please
click here
.
Globally, prescribing information varies; refer to the individual country product label for complete information.
Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including beliefs about the potential for VASCEPA (marketed as VAZKEPA in Europe); beliefs about icosapent ethyl (IPE)’s role concerning appropriate patients suffering from cardiovascular disease (CVD) and potential population health impact, as well as general beliefs about the safety and effectiveness of VASCEPA. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin's filings with the U.S. Securities and Exchange Commission, including Amarin’s annual report on Form 10-K for the full year ended 2024. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. Amarin undertakes no obligation to update or revise the information contained in its forward-looking statements, whether as a result of new information, future events or circumstances or otherwise. Amarin’s forward-looking statements do not reflect the potential impact of significant transactions the company may enter into, such as mergers, acquisitions, dispositions, joint ventures or any material agreements that Amarin may enter into, amend or terminate. Availability of Other Information About Amarin communicates with its investors and the public using the company website (
www.amarincorp.com
) and the investor relations website (
www.amarincorp.com/investor-relations
) including but not limited to investor presentations and FAQs, Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Amarin posts on these channels and websites could be deemed to be material information. As a result, Amarin encourages investors, the media and others interested in Amarin to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Amarin’s investor relations website and may include social media channels. The contents of Amarin’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.
Amarin Contact Information
Investor & Media Inquiries:
Mark Marmur
Amarin Corporation plc
PR@amarincorp.com
Investor.relations@amarincorp.com
_________________________
1
American Heart Association. Heart Disease and Stroke Statistics—2020 Update: A Report From the American Heart Association.
Circulation
. 2020;141:e139-e596.
2
Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for adjunctive dyslipidemia therapy in hypertriglyceridemia management.
J Am Coll
Cardiol
. 2018;72(3):330-343.
3
Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease.
Am J
Cardiol
. 2016;118:138-145.
4
Toth PP, Granowitz C, Hull M, et al. High triglycerides are associated with increased cardiovascular events, medical costs, and resource use: A real-world administrative claims analysis of statin-treated patients with high residual cardiovascular risk.
J Am Heart Assoc
. 2018;7(15):e008740.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
